Schedule I Controlled Substance Updated 2026-05-29

Psilocybin Laws in Federal (United States)

Psilocybin remains a Schedule I controlled substance under the federal Controlled Substances Act. However, FDA and VA activity in 2026 points to faster research and review pathways for psychedelic medicines, especially in serious mental illness and veteran-focused studies.

Official source trail

Research momentum is not legalization

The federal page should be read as a boundary map: research, FDA review, Right to Try discussion, and VA trials are different from state-regulated access or general public legality.

What changed

Federal agencies are being pushed to accelerate serious mental-health research and psychedelic medicine development.

What did not change

Psilocybin remains Schedule I federally, and public medical access still depends on trials, FDA approval, or lawful state programs.

White House April 2026 executive order page about psychedelic research and veterans
White House

Executive order

Federal research acceleration is a serious policy signal. It is not broad legalization or routine VA treatment.

Open official source
FDA April 2026 announcement about psychedelic medicine development actions
FDA

FDA development actions

FDA follow-up named psilocybin for depression, methylone for PTSD, and noribogaine research while keeping approval standards intact.

Open official source
VA May 2026 MDMA-assisted mental health therapy trial announcement
VA

VA trial boundary

VA announced an MDMA-assisted therapy trial and says clinical use outside research depends on FDA approval.

Open official source

Current Legal Status

Schedule I Controlled Substance

Psilocybin is Schedule I under 21 U.S.C. § 812. First-offense personal possession carries up to one year; distribution up to 20 years. Federal prosecution for personal use in decriminalized states is rare.

Key Legislation

FDA Breakthrough Therapy Designation has applied to sponsor-led psychedelic drug-development programs, and the April 18, 2026 executive order directed federal agencies to accelerate serious mental-illness treatment development. Those actions do not approve psilocybin, reschedule it, or create routine VA treatment.

Therapeutic Programs

No federally licensed psilocybin therapy program exists. FDA-regulated clinical trials are ongoing, and VA announced a 2026 MDMA-assisted therapy trial while stating that clinical use outside research depends on FDA approval.

Clinical Trials

Clinical-trial status changes frequently. Search ClinicalTrials.gov for 'psilocybin' and verify sponsor, location, recruiting status, inclusion criteria, and last-update date before relying on a study listing.

Advocacy Organizations

MAPS, COMPASS Pathways, Usona Institute, Healing Advocacy Fund, American Psychedelic Practitioners Association.

Related Resources

See how Federal (United States) compares to neighboring states and find therapy options for residents: